메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Mabwell Announces First Patient Dosed in the US Clinical Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated with ADCs

SHANGHAI, Aug. 12, 2025 -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced the first patient dosing in the U.S. for a clinical study of its novel nectin-4-targeting antibody-drug conjugate (Bulumtatug Fuvedotin, or BFv, R&D code: 9MW2821) in triple-negative breast cancer (TNBC) patients previously treated with antibody-drug conjugate (ADC). This is the first overseas clinical study of 9MW2821, representing a significant step in Mabwell's global development of ADC therapeutics. The multicenter clinical study (NCT06908928) aims to ev
- 김갑성 기자
- 2025-08-12 22:00
인타스 앤 어코드, 프로티아 바이오솔루션스 인수 계약 체결

아마다바드, 인도, 2025년 8월 12일 -- 다국적 제약사 인타스 파마슈티컬스(Intas Pharmaceuticals)의 자회사 어코드 플라스마(Accord Plasma B.V.)가 네덜란드와 벨기에를 중심으로 활동하는 플라스마 유래 의약품(plasma-derived medicinal products•PDMP) 분야 선도기업인 프로티아 바이오솔루션스 벨기에(Prothya Biosolutions Belgium BV) 및 이 회사의 모든 자회사 지분 100%를 인수하는 계약을 체결했다. 규제 당국의 승인을 포함한 통상적인 거래 종결 조건이 충족되는 대로 인수는 마무리될 예정이다. 이번 인수로 인타스와 어코드는 PDMP 시장에서 글로벌 입지를 구축하려는 오랜 목표에 중요한 진전을 이뤘다. 인타스는 인도 내에서 확립한 리더십을 바탕으로 진정한 국제적 영향력을 발휘할 것으로 기대된다. 프로티아 바이오솔루션스는 암스테르담과 브뤼셀에 주요 사무소를 두고 있으며 헝가리 전역에 플라스마 수집 센터를 운영 중이다. 직원 수는 약 1200명인 유럽 최대 플라스마 분획업체 중 하나다. 2021년 본래 벨기에 적십자(Belgian Red
- 김갑성 기자
- 2025-08-12 20:01
Aquedeon Medical Inc. Receives FDA Approval to Expand Clinical Trial of Duett Vascular Graft System

[ 메디채널 김갑성 기자 ] CAUTION: Investigational device. Limited by Federal (or United States) law to investigational use. SUNNYVALE, Calif., Aug. 12, 2025 -- Aquedeon Medical Inc. (AMI) is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved the expansion of its Investigational Device Exemption (IDE) clinical trial evaluating the Duett Vascular Graft System (Duett System), a novel device designed to facilitate open surgical repair of aortic arch aneurysms and dissections, including hybrid procedures. AMI is developing the Duett System to address a critica
- 김갑성 기자
- 2025-08-12 20:00
Manipal Hospitals Kolkata completes 50 successful TAVR cases

KOLKATA, India, Aug. 12, 2025 -- Manipal Hospitals - EM Bypass (erstwhile Medica Superspecialty Hospital), Kolkata is thrilled to announce the completion of 50 successful Transcatheter Aortic Valve Replacement (TAVR) cases, establishing the facility as a regional market leader in structural cardiac procedures in Eastern India. TAVR is a minimally invasive approach of treating patients with severe aortic stenosis who are at high or prohibitive risk for traditional open-heart surgery. This is more than just a number, it demonstrates a patient's faith, cutting-edge infrastructure,
- 김갑성 기자
- 2025-08-12 17:29
Life (Insurance) starts at 30 - when Aussies wish they'd signed up for coverage

BRISBANE, Australia, Aug. 12, 2025 -- One quarter of Australians with life insurance wish they'd taken out their policy earlier in life, according to a new Budget Direct Life Insurance survey. The poll of 997 Australians with life insurance also reveals the age they recommend signing up. Around 39% of people surveyed felt the best time to invest in life insurance was in your 30s, followed by your 20s (28%) and in your 40s (23%). Only 10% of respondents recommended waiting until your 50s or later. "The top two moments of any adult's life would have to be the birth of
- 김갑성 기자
- 2025-08-12 12:03
Fosun Pharma's Small Molecule Innovative Drug XH-S004 Achieves Overseas Licensing for a Potential Total of $645 Million

SHANGHAI, Aug. 12, 2025 -- On August 11, Fosun Pharma (SSE:600196, HKEX: 02196) announced that its subsidiary Fosun Pharma Industrial has signed a License Agreement with Expedition Therapeutics Inc.(Expedition) to grant Expedition the rights to develop, manufacture, and commercialize XH-S004, an orally administered dipeptidyl peptidase 1 (DPP-1) inhibitor independently developed by Fosun Pharma, in all regions globally except Chinese Mainland, Hong Kong SAR and Macau SAR. Fosun Pharma will retain the rights to develop, manufacture, and commercialize XH-S004 in Chinese Mainland, Hong Kong SAR
- 김갑성 기자
- 2025-08-12 09:36
Sleep Health Week: Researchers Recruiting Now for CBD Insomnia Trial

During Sleep Health Week (11-15 August 2025), Australians living with insomnia are reminded that a new treatment is on the horizon – with clinical trial sites actively recruiting now. MELBOURNE, Australia, Aug. 12, 2025 -- Avecho Biotechnology Limited (Avecho) is today alerting Australians to recruitment efforts for the largest ever clinical trial ('the Trial') for the treatment of insomnia with a pharmaceutical cannabidiol (CBD) product – with clinical trial sites now live across the country. The Trial is a placebo-controlled study assessing the use of CBD for insomnia, recruit
- 김갑성 기자
- 2025-08-12 08:32
Intas & Accord signs Agreement to acquire Prothya Biosolutions

AHMEDABAD, India, Aug. 11, 2025 -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, has announced the execution of an agreement to acquire 100% of Prothya Biosolutions Belgium BV and each of its subsidiaries, a leading plasma-derived medicinal products (PDMP) business based primarily in the Netherlands and Belgium. Subject to the satisfaction of customary closing conditions, including regulatory clearances, the deal is anticipated to close shortly. This proposed acquisition marks a significant step in Intas and Accord's long-standing ambition to establish a global pre
- 김갑성 기자
- 2025-08-11 21:41
AGEBOX Presents iKids-Growth: Pioneering Safe and Natural Support for Children's Height Development

RICHMOND, VA., Aug. 11, 2025 -- In the field of pediatric development, a significant advancement is taking shape. For years, parents have navigated a marketplace of nutritional aids—from basic multivitamins to protein powders—with little more than hope to guide them. iKids-Growth marks a meaningful step forward, moving beyond passive nutritional support and toward a more proactive, biologically-informed strategy. AGEBOX, a trailblazer in pediatric health, is responding to the growing parental demand for safe, hormone-free height support—with iKids-Growth, the first-ever supple
- 김갑성 기자
- 2025-08-11 21:30
Caliber Enters 25th Year of Empowering Global Pharma with GxP Digital Solutions

HYDERABAD, India, Aug. 11, 2025 -- Caliber, a leading global provider of GxP-compliant digital solutions for the life sciences industry, proudly announces the start of its 25th year of operations. With over two decades of expertise, Caliber has helped pharmaceutical and biotechnology companies in 17 countries enhance quality systems, streamline operations, and ensure regulatory compliance. To mark this milestone, Caliber unveiled a new anniversary logo, officially installed at the company's India headquarters in Hyderabad. "The logo brings together th
- 김갑성 기자
- 2025-08-11 21:22

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2025-08-30_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 08월 31일 01시 20분